Entrada Therapeutics
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $875 | $1,299 | $1,614 | $1,950 |
Gross Profit | 70 | 413 | -36,747 | 1,950 |
EBITDA | -38,874 | -41,857 | -42,250 | -41,891 |
EBIT | -39,679 | -39,072 | -43,480 | -42,925 |
Net Income | -39,717 | -39,164 | -44,134 | -43,103 |
Net Change In Cash | 875 | 1,299 | 1,614 | 1,950 |
Free Cash Flow | -41,739 | -31,996 | -28,142 | -29,764 |
Cash | 76,444 | 90,394 | 93,286 | 72,482 |
Basic Shares | 41,836 | 41,371 | 41,462 | 41,339 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $25,421 | $210,782 | $129,013 | $25,260 |
Gross Profit | 21,325 | 210,782 | 129,013 | -1,895 |
EBITDA | -142,401 | 70,258 | 14,897 | -95,353 |
EBIT | -142,826 | 66,485 | 12,056 | -97,248 |
Net Income | -143,750 | 65,626 | -6,685 | -87,457 |
Net Change In Cash | 25,421 | 210,782 | 129,013 | 25,260 |
Free Cash Flow | -129,553 | -44,715 | 134,189 | -96,673 |
Cash | 90,394 | 101,211 | 67,602 | 45,157 |
Basic Shares | 41,371 | 39,003 | 33,050 | 31,293 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.95 |
2025-12-31 | -$0.94 |
2025-09-30 | -$1.06 |
2025-06-30 | -$1.04 |